Top

Published in:

01-04-2014 | Research Article

Ki67 and TP53 expressions predict recurrence of non-muscle-invasive bladder cancer

Authors: Lujia Wang, Chenchen Feng, Guanxiong Ding, Qiang Ding, Zhongwen Zhou, Haowen Jiang, Zhong Wu

Published in: Tumor Biology | Issue 4/2014

Abstract

Tumor markers Ki67, TP53, and TP63 are common labels in the diagnosis of bladder cancer (BCa) around the world. The combination of those biomarkers may have advantages in predicting BCa prognosis and non-muscle-invasive bladder cancer (NMIBC) postoperative recurrence. We investigated the immunohistochemical profiles of 313 bladder cancer samples classified under the WHO/ISUP (2004) grading scale and the UICC-TNM (2002) classification. Then we investigated their predictive value in the tumor recurrence of 270 NMIBC patients after TURBT. Expression of Ki67 correlates with grade, stage, tumor size, and tumor numbers. Semiquantitative evaluation of TP53 correlates with grade and invasive conditions. The positive expression rate of TP63 correlated with tumor grade and stage. The combined effect of TP53 and Ki67 revealed a predictive value in NMIBC recurrence. However, the positive TP63 expression did not show any protective effect in NMIBC recurrence. The expression of TP53 and Ki67 could be used to predict the risk of NMIBC recurrence postoperatively.

Cordon-Cardo C et al. Molecular alterations associated with bladder cancer initiation and progression. Scand J Urol Nephrol Suppl. 2008;8:154–65.CrossRef

Epstein JI, Amin VR, Reuter FK, et al. The World Health Organization/International Society of Urological Pathology Consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. The Bladder Consensus Conference Committee. Am J Surg Pathol. 1998;22:1435–48.PubMedCrossRef

Larsson P, Wijkstrom H, Thorstenson A, et al. A population-based study of 538 patients with newly detected urinary bladder neoplasms followed during 5 years. Scand J Urol Nephrol. 2003;37:195–201.PubMedCrossRef

Fernandez-Gomez J, Madero R, Solsona E, et al. Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette-Guerin: the CUETO scoring model. J Urol. 2009;182(5):2195–203.PubMedCrossRef

Madersbacher S, Hochreiter W, Burkhard F, et al. Radical cystectomy for bladder cancer today—a homogeneous series without neoadjuvant therapy. J Clin Oncol. 2003;21(4):690–6.PubMedCrossRef

Bassi P, Ferrante GD, Piazza N, et al. Prognostic factors of outcome after radical cystectomy for bladder cancer: a retrospective study of a homogeneous patient cohort. J Urol. 1999;161(5):1494–7.PubMedCrossRef

Evans CP, Debruyne F, Payne H, et al. Bladder cancer: management and future directions. Eur Urol Suppl. 2007;6:365–73.CrossRef

Millan-Rodriguez F, Chechile-Toniolo G, Salvador-Bayarri J, et al. Multivariate analysis of the prognostic factors of primary superficial bladder cancer. J Urol. 2000;163:73–8.PubMedCrossRef

Pruthi RS, Baldwin N, Bhalani V, et al. Conservative management of low risk superficial bladder tumors. J Urol. 2008;179(1):87–90.PubMedCrossRef

10.

Sylvester R, Oosterlinck W, van der Meijden A, et al. Treatment of superficial bladder tumors: achievements and needs. The EORTC Genitourinary Group. Eur Urol. 2000;37 Suppl 3:1–9.PubMed

11.

Evans C, Debruyne F, Payne H, et al. Bladder cancer: management and future directions. Eur Urol Suppl. 2006;6:365–73.CrossRef

12.

Bryan RT, Zeegers MP, James ND, et al. Biomarkers in bladder cancer. BJU Int. 2010;105:608–13.PubMedCrossRef

13.

Sauter G, Algaba F, Amin M., et al. Tumours of the urinary system: non-invasive urothelial neoplasias. In: Eble JN, Sauter G, Epstein Jl, Sesterhenn I, eds. WHO classification of classification of tumours of the urinary system and male genital organs. Lyon: IARCC Press, 2004, pp. 29–34.

14.

Sobin LH, Gospodariwicz M, Wittekind C. (eds). TNM classification of malignant tumors. UICC International Union Against Cancer. 7th edn. Wiley-Blackwell, 2009; pp. 262–265.

15.

Wang L, Feng C, Ding G, et al. Relationship of TP53 and Ki67 expression in bladder cancer under WHO 2004 classification. J BUON. 2013;18(2):420–4.PubMed

16.

Feng CC, Wang PH, Ding Q, Guan M, Zhang YF, Jiang HW, et al. Expression of pigment epithelium-derived factor and tumor necrosis factor-α is correlated in bladder tumor and is related to tumor angiogenesis. Urol Oncol. 2013;31(2):241–6.PubMedCrossRef

17.

Feng C, Wu Z, Guo T, Jiang H, Guan M, Zhang Y, et al. BLCA-4 expression is related to MMP-9, VEGF, IL-1α and IL-8 in bladder cancer but not to PEDF. TNF-α or angiogenesis. Pathol Biol (Paris). 2012;60:e36–40.CrossRef

18.

Feng CC, Wang PH, Guan M, Jiang HW, Wen H, Ding Q, et al. Urinary BLCA-4 is highly specific for detection of bladder cancer in Chinese Han population and is related to tumour invasiveness. Folia Biol (Praha). 2011;57:242–7.

19.

Sylvester RJ, van der Meijden AP, Oosterlinck W, et al. Predicting recurrence and progression in individual patients with stage TaT1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol. 2006;49(3):466–5.PubMedCrossRef

20.

Montironi R, Mazzucchelli R, Colanzi P, et al. Improving interobserver agreement and certainly level in diagnosing and grading papillary urothelial neoplasms. Usefulness of a Bayesian belief network. Eur Urol. 2002;41:449–57.PubMedCrossRef

21.

Yurakh A, Ramos D, Calabuig-Frinas S, et al. Molecular and immunohistochemical analysis of the prognostic value of cell-cycle regulators in urothelial neoplasms of the bladder. Eur Urol. 2006;50:506–15.PubMedCrossRef

22.

Oosterhuis J, Schapers R, Janssen-Heijnen M, et al. MIB-1 as a proliferative marker in transitional cell carcinoma of the bladder. Clinical significance and comparison with other prognostic factors. Cancer. 2000;88:2598–605.PubMedCrossRef

23.

Wu T, Chen J, Lee Y, et al. The role of BCL-2, TP53 and Ki67 index in predicting tumor recurrence for low grade superficial transitional cell bladder carcinoma. J Urol. 2000;163:758–60.PubMedCrossRef

24.

Gonzalez-Campora R, Davalos-Casanova A, et al. Apoptotic and proliferation indexes in primary superficial bladder tumors. Cancer Lett. 2006;242:266–72.PubMedCrossRef

25.

Santos L, Amaro T, Pereira S, et al. Expression of cell-cycle regulatory proteins and their prognostic value in superficial low-grade urothelial cell carcinoma of the bladder. EJSO. 2003;29:74–80.PubMedCrossRef

26.

Mulder A, Van Hootegem J, Sylvester R, et al. Prognostic factors in bladder carcinoma: histological parameters and expression of a cell cycle related nuclear antigen (Ki67). J Pathol. 1992;166:37–43.PubMedCrossRef

27.

Vet JA, Bringuier PJ, Poddighe HF, et al. TP53 mutations have no additional prognostic value over stage in bladder cancer. Br J Cancer. 1994;70:496–500.PubMedCentralPubMedCrossRef

28.

Erill N, Colomer A, Verdú M, et al. Genetic and immunophenotype analyses of TP53 in bladder cancer: TP53 alterations are associated with tumor progression. Diagn Mol Pathol. 2004;13(4):217–23.PubMedCrossRef

29.

Comperat E, Camparo P, Haus R, et al. Immunohistochemical expression of p63, p53 and MIB-1in urinary bladder carcinoma. A tissue microarray study of 158 cases. Virchows Arch. 2006;448:319–24.PubMedCrossRef

30.

Liukkonen T, Rajala P, Raitanen M, et al. Prognostic value of MIB-1 score, TP53, EGFr, mitotic index and papillary status in primary superficial (stage pTa/pT1) bladder cancer: a prospective comparative study. Eur Urol. 1999;36:393–400.PubMedCrossRef

31.

Shariat S, Kim J, Raptidis G, et al. Association of p63 and p21 expression with clinical outcome in patients with carcinoma in situ of the urinary bladder. Urology. 2003;61:1140–5.PubMedCrossRef

32.

Friedrich M, Riethdorf S, Erbersdobler A, et al. Relevance of p53 gene alterations for tumor recurrence in patients with superficial transitional cell carcinoma of the bladder. J Urol. 1996;155:1754–7.CrossRef

33.

Gontero P, Casetta G, Zitella A, et al. Evaluation of TP53 protein over expression, Ki67 proliferative activity and mitotic index as markers of tumor recurrence in superficial transitional cell carcinoma of the bladder. Eur Urol. 2000;38:287–96.PubMedCrossRef

34.

Yang A, McKeon F, et al. P63 and P73: p53 mimics, menaces and more. Nat Rev Mol Cell Biol. 2000;1:100–207.CrossRef

35.

Park B, Lee S, Kim J, et al. Frequent alteration of p63 expression in human primary carcinomas. Cancer Res. 2000;60:3370–4.PubMed

36.

Urist M, Di Como C, Lu M, et al. Loss of p63 expression is associated with tumor progression in bladder. Am J Patho. 2002;161:1199–206.CrossRef

Title: Ki67 and TP53 expressions predict recurrence of non-muscle-invasive bladder cancer
Authors: Lujia Wang
Chenchen Feng
Guanxiong Ding
Qiang Ding
Zhongwen Zhou
Haowen Jiang
Zhong Wu
Publication date: 01-04-2014
Publisher: Springer Netherlands
Published in: Tumor Biology / Issue 4/2014
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI: https://doi.org/10.1007/s13277-013-1384-9

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2014

CCNG2 expression is downregulated in colorectal carcinoma and its clinical significance

Hexokinase 2 overexpression promotes the proliferation and survival of laryngeal squamous cell carcinoma

Changes in the expression of cyclin G2 in esophageal cancer cell and its significance

Decorin-mediated inhibition of cholangiocarcinoma cell growth and migration and promotion of apoptosis are associated with E-cadherin in vitro

An updated meta-analysis of transforming growth factor-β1 gene: three polymorphisms with gastric cancer

Prognostic significance of dickkopf-1 overexpression in solid tumors: a meta-analysis

Keynote webinar | Spotlight on antibody–drug conjugates in cancer